Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Update

Key Points

• Short interest surge: As of March 31 short interest jumped 48.8% to 12,265,390 shares (about 16.8% of the float), leaving a days-to-cover ratio of 6.3.
• Stock and valuation snapshot: OLMA traded at $16.30 (up 2.3%) with a $1.42 billion market cap, a 52‑week range of $3.89–$36.26, and a negative trailing PE reflecting current losses.
• Analyst and insider activity: Analysts hold a consensus "Moderate Buy" with an average target of $44.40, while insiders sold 153,489 shares (~$4.19M) in the last 90 days and institutional investors own about 91.8% of the stock.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 12,265,390 shares, an increase of 48.8% from the March 15th total of 8,240,774 shares. Approximately 16.8% of the company's shares are short sold. Based on an average trading volume of 1,946,705 shares, the days-to-cover ratio is currently 6.3 days.

Olema Pharmaceuticals Trading Up 2.3%

NASDAQ:OLMA traded up $0.37 on Tuesday, reaching $16.30. The company's stock had a trading volume of 794,986 shares, compared to its average volume of 1,592,260. Olema Pharmaceuticals has a 1-year low of $3.89 and a 1-year high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.95 and a current ratio of 9.95. The firm has a market cap of $1.42 billion, a PE ratio of -8.76 and a beta of 2.17. The business's 50-day moving average price is $19.30 and its two-hundred day moving average price is $19.69.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its earnings results on Monday, March 16th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.01. Equities research analysts anticipate that Olema Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

Insider Transactions at Olema Pharmaceuticals

In related news, Director Cyrus Harmon sold 10,000 shares of Olema Pharmaceuticals stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total transaction of $268,800.00. Following the completion of the sale, the director directly owned 727,770 shares of the company's stock, valued at $19,562,457.60. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total value of $606,250.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 153,489 shares of company stock worth $4,194,800 over the last 90 days. 16.36% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of OLMA. EverSource Wealth Advisors LLC boosted its position in shares of Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company's stock worth $31,000 after buying an additional 1,232 shares during the period. Torren Management LLC acquired a new position in shares of Olema Pharmaceuticals during the fourth quarter worth about $44,000. Russell Investments Group Ltd. acquired a new position in shares of Olema Pharmaceuticals during the third quarter worth about $53,000. American Century Companies Inc. acquired a new position in shares of Olema Pharmaceuticals during the second quarter worth about $54,000. Finally, Creative Planning acquired a new position in shares of Olema Pharmaceuticals during the second quarter worth about $83,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. Jefferies Financial Group assumed coverage on Olema Pharmaceuticals in a research note on Thursday, March 19th. They set a "buy" rating and a $40.00 price objective for the company. The Goldman Sachs Group decreased their price objective on Olema Pharmaceuticals from $38.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, March 18th. Wolfe Research assumed coverage on Olema Pharmaceuticals in a research note on Friday, March 27th. They set a "peer perform" rating for the company. Finally, JPMorgan Chase & Co. lifted their price objective on Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 18th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $44.40.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.